Taysha Gene Therapies presents new supplemental data analysis from REVEAL study

Taysha Gene Therapies (TSHA) announced results from a new supplemental data analysis from Part A of the REVEAL Phase 1/2 adult/adolescent and pediatric trials evaluating TSHA-102 in females with Rett syndrome at the 54th Child Neurology Society Annual Meeting. The analysis provides supportive evidence of additional functional gains in skills and improvements across core disease characteristics that are outside of the natural history defined developmental milestones, further highlighting the consistent, multi-domain impact of TSHA-102 on activities of daily living. New supplemental analysis of efficacy scales provides supportive evidence of additional functional gains, with 100% of patients demonstrating multiple skill gains/improvements outside the natural history defined developmental milestones